Maintenance of all applications is scheduled on 28/03/2023 from 19:00 to 23:30 and on 29/03/2023 from 19:00 to 23:30. This could cause a system interruption during this time.
Pre–commercial procurement to buy R&D services for the development of a solution for analysis in liquid biopsies of solid tumours based on NGS technology
Description
The mutational profiling of tumours requires complex, invasive and expensive procedures but is
rapidly becoming essential for an efficient and adequate provision of care for cancer patients, especially when the disease
has already advanced to metastatic conditions, in which the identification of tumour biomarkers is relevant to identify the
best targeted therapy. However, access to tumour tissue remains a limiting factor for the assessment of biomarkers, and
mounting evidence suggests that may even be inadequate to capture the clonal heterogeneity that often drives resistance.
The assessment of circulating biomarkers is rapidly gaining ground as a non-invasive alternative that offers the additional
possibility of serially monitoring disease evolution and the potential to obtain a more comprehensive picture of the tumour
genetic heterogeneity. However, the current development trajectory for large cfDNA tests is heavily reliant on costly, high
throughput centralized sequencing and appears ill-suited for European common practice.
The oncNGS PCP aims at developing an integrated solution for predictive, prognostic and diagnostic analysis in liquid biopsies
of solid tumours (including appropriate haematological indications) based on NGS technology.
This PCP tackles the common global unmet need in oncology to profile multiple tumours at the molecular level in the broadest
possible way, promoting an economically sustainable and de-centralised model that allows a secure and transparent access to
sensitive data. All partners in this consortium do agree that they face a common challenge in providing ‘the best NGS tests, for
all solid and lymphoid tumours, forever’. They agree that a commonly identified procurement meets a need that is shared by all
procurers in the Buyers Group of the project that forms the object of the here proposed PCP procurement ‘oncNGS’.
More information regarding the goal of the oncNGS PCP and the PCP Challenge can be found in the different annexes.
Pre–commercial procurement to buy R&D services for the development of a solution for analysis in liquid biopsies of solid tumours based on NGS technology
Pre–commercial procurement to buy R&D services for the development of a solution for analysis in liquid biopsies of solid tumours based on NGS technology